Type 1 diabetes, also known as juvenile diabetes or insulin-dependent diabetes, is a chronic condition that disrupts the body's ability to regulate blood sugar levels. It is a result of the immune system mistakenly attacking the pancreas's beta cells, which are responsible for producing insulin.
The primary categories of medications for managing type 1 diabetes include rapid-acting insulin analogs, long-acting insulin analogs, premix insulin analogs, and others. Rapid-acting insulin analogs are synthetic forms of insulin engineered to have a faster onset, a more rapid peak effect, and a shorter duration of action compared to natural insulin. Various devices like insulin pumps, insulin pens, and blood glucose meters are employed for managing the condition. These devices are used by individuals of various age groups, both children and adults, and cater to different end-users, including hospitals, research institutes, and home care settings.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The type 1 diabetes market research report is one of a series of new reports from The Business Research Company that provides type 1 diabetes market statistics, including type 1 diabetes industry global market size, regional shares, competitors with a type 1 diabetes market share, detailed type 1 diabetes market segments, market trends and opportunities and any further data you may need to thrive in the type 1 diabetes industry. This type 1 diabetes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The type 1 diabetes market size has grown rapidly in recent years. It will grow from $11.82 billion in 2024 to $13.5 billion in 2025 at a compound annual growth rate (CAGR) of 14.2%. The growth in the historic period can be attributed to growing demand for effective treatments, growing public awareness of type 1 diabetes, growing funds for drug development, incremental healthcare spending across the world.
The type 1 diabetes market size is expected to see rapid growth in the next few years. It will grow to $22.43 billion in 2029 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to growing awareness of early checkups for diabetes, growing adoption of home-care settings, increasing research for advanced drugs, increasing awareness of the consumption of nutritional products. Major trends in the forecast period include advanced insulin formulations, advancements in drugs and treatments, artificial pancreas systems, personalized medicine approaches.
The forecast of 13.5% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. adoption of advanced closed-loop insulin pumps by inflating prices of continuous glucose monitoring (CGM) sensors developed in Ireland and Switzerland, resulting in poorer glycemic control and higher endocrinology costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The anticipated growth of the type 1 diabetes market is expected to be fueled by increasing government efforts to tackle diabetes. Government initiatives encompass a range of actions, policies, programs, or projects undertaken by governmental authorities to address specific issues, achieve objectives, or instigate positive changes in various aspects of society. Notably, government bodies are launching multiple initiatives aimed at combating diabetes, including type 1 diabetes. These initiatives are geared towards lowering diabetes risks and ensuring that all individuals diagnosed with diabetes have access to fair, comprehensive, affordable, and high-quality treatment and care. An illustrative example is the collaboration between the Canadian government and JDRF Canada, a non-profit organization based in Canada, which pledged $33 million in support of 12 research projects focused on the prevention, detection, management, and treatment of diabetes in July 2023. This funding will also aid the establishment of a national screening research consortium that will unite experts and individuals affected by diabetes to advance early-stage, pre-symptomatic type 1 diabetes screening in Canada. Consequently, the upsurge in government initiatives aimed at combatting diabetes is a driving force behind the growth of the type 1 diabetes market.
The rising prevalence of obesity and heart disease is expected to drive the growth of the type 1 diabetes market in the future. Obesity is a medical condition characterized by an unhealthy accumulation of excess body fat, while heart disease encompasses various conditions that impact the heart and blood vessels. Excess body weight heightens the risk of insulin resistance, which can result in elevated blood sugar levels and the onset of type 1 diabetes. Additionally, high blood sugar levels can harm blood vessels and nerves that regulate the heart and blood vessels, contributing to heart disease. For instance, in September 2024, the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, reported that from August 2021 to August 2023, the prevalence of severe obesity among adults was 9.4%. This rate was particularly high in the 20-39 age group at 9.5% and in the 40-59 age group at 12.0%, while only 6.6% of adults aged 60 and older were categorized as severely obese. Similarly, in September 2024, data published by the British Heart Foundation, a UK-based cardiovascular research charity, indicated that approximately 7.6 million people in the UK are affected by heart and circulatory diseases, comprising around 4 million males and 3.6 million females living with these conditions. These diseases account for about 27% of all deaths in the UK, resulting in over 170,000 deaths annually, or approximately 480 deaths each day, which translates to one death every three minutes. Therefore, the increasing rates of obesity and heart disease are fueling the growth of the type 1 diabetes market.
Prominent companies operating within the type 1 diabetes sector are concentrating their efforts on the development of cutting-edge solutions, including technologies like SmartGuard, as part of their strategy to maintain their market position. SmartGuard is a technology designed to assist individuals with diabetes, particularly those who may have concerns about hypoglycemia or lack awareness of it. An illustrative case in point is Medtronic PLC, an Irish-based company specializing in medical technology, services, and solutions, which introduced the MiniMed 780G system featuring advanced SmartGuard technology in March 2022. This innovative product represents a next-generation closed-loop insulin pump system that streamlines the management of type 1 diabetes. The system automates the administration of basal insulin and correction boluses at five-minute intervals, helping diabetes patients better avoid both high and low blood sugar levels. Furthermore, this system enables patients to reduce glucose level fluctuations and maintain their levels within predetermined parameters, ultimately enhancing their quality of life and achieving improved clinical outcomes.
In March of 2023, the French pharmaceutical and healthcare company, Sanofi, completed the acquisition of Provention Bio Inc. for a total of $2.9 billion. This strategic move by Sanofi is intended to bolster its presence in the realm of immune-mediated diseases and disease-modifying therapies, particularly in areas with significant unmet medical needs. Additionally, Sanofi aims to leverage its expertise in diabetes to maximize the potential of transformative therapies. Provention Bio Inc., based in the United States, specializes in the production of biopharmaceutical products, with a focus on type 1 diabetes.
Major companies operating in the type 1 diabetes market are Johnson and Johnson Limited, Merck and Co. Inc., Sanofi-Aventis LLC., AstraZeneca PLC, Abbott Laboratories, Medtronic PLC, Eli Lilly and Co Ltd., Novo Nordisk A/S, Vertex Pharmaceuticals Incorporated, Dexcom Inc., Insulet Corporation, Tandem Diabetes Care Inc., Adaptive Biotechnologies Corporation, Xeris Pharmaceuticals Inc., MannKind Corporation, Biocon Ltd., Virta Health Corp., Bigfoot Biomedical Inc., ViaCyte Inc., Beta Bionics Inc., Adocia SA, Senseonics Holdings Inc., Zealand Pharmaceuticals A/S, Sigilon Therapeutics Inc., Provention Bio Inc.
North America was the largest region in the type 1 diabetes market in 2024. The regions covered in type 1 diabetes report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the type 1 diabetes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The type 1 diabetes market consists of sales of drugs used to treat type 1 diabetes such as autoimmune type 1 diabetes and idiopathic type 1 diabetes. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Type 1 Diabetes Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on type 1 diabetes market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for type 1 diabetes ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The type 1 diabetes market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Product Type: Rapid Acting Insulin Analogs; Long-Acting Insulin Analogs; Premix Insulin Analogs; Others Product Types
- 2) By Device: Insulin Pump; Insulin Pen; Blood Glucose Meter
- 3) By Application: Childrens; Adults
- 4) By End-User: Hospital; Research Institutes; Home Care
- Subsegments:
- 1) By Rapid Acting Insulin Analogs: Insulin Lispro; Insulin Aspart; Insulin Glulisine
- 2) By Long-Acting Insulin Analogs: Insulin Detemir; Insulin Glargine; Insulin Degludec
- 3) By Premix Insulin Analogs: Premixed Insulin Lispro; Premixed Insulin Aspart; Premixed Insulin Glargine
- 4) By Other Product Types: Insulin Pumps; Continuous Glucose Monitoring Systems; Non-Insulin Medications; Combination Therapies
- Companies Mentioned: Johnson and Johnson Limited; Merck and Co. Inc.; Sanofi-Aventis LLC.; AstraZeneca PLC; Abbott Laboratories; Medtronic Plc; Eli Lilly and Co Ltd.; Novo Nordisk A/S; Vertex Pharmaceuticals Incorporated; Dexcom Inc.; Insulet Corporation; Tandem Diabetes Care Inc.; Adaptive Biotechnologies Corporation; Xeris Pharmaceuticals Inc.; MannKind Corporation; Biocon Ltd.; Virta Health Corp.; Bigfoot Biomedical Inc.; ViaCyte Inc.; Beta Bionics Inc.; Adocia SA; Senseonics Holdings Inc.; Zealand Pharmaceuticals A/S; Sigilon Therapeutics Inc.; Provention Bio Inc.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Type 1 Diabetes Market Characteristics
3. Type 1 Diabetes Market Trends And Strategies
4. Type 1 Diabetes Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
- 4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Type 1 Diabetes Growth Analysis And Strategic Analysis Framework
- 5.1. Global Type 1 Diabetes PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Type 1 Diabetes Market Growth Rate Analysis
- 5.4. Global Type 1 Diabetes Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Type 1 Diabetes Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Type 1 Diabetes Total Addressable Market (TAM)
6. Type 1 Diabetes Market Segmentation
- 6.1. Global Type 1 Diabetes Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Rapid Acting Insulin Analogs
- Long-Acting Insulin Analogs
- Premix Insulin Analogs
- Others Product Types
- 6.2. Global Type 1 Diabetes Market, Segmentation By Device, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Insulin Pump
- Insulin Pen
- Blood Glucose Meter
- 6.3. Global Type 1 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Childrens
- Adults
- 6.4. Global Type 1 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital
- Research Institutes
- Home Care
- 6.5. Global Type 1 Diabetes Market, Sub-Segmentation Of Rapid Acting Insulin Analogs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Insulin Lispro
- Insulin Aspart
- Insulin Glulisine
- 6.6. Global Type 1 Diabetes Market, Sub-Segmentation Of Long-Acting Insulin Analogs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Insulin Detemir
- Insulin Glargine
- Insulin Degludec
- 6.7. Global Type 1 Diabetes Market, Sub-Segmentation Of Premix Insulin Analogs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Premixed Insulin Lispro
- Premixed Insulin Aspart
- Premixed Insulin Glargine
- 6.8. Global Type 1 Diabetes Market, Sub-Segmentation Of Other Product Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Insulin Pumps
- Continuous Glucose Monitoring Systems
- Non-Insulin Medications
- Combination Therapies
7. Type 1 Diabetes Market Regional And Country Analysis
- 7.1. Global Type 1 Diabetes Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Type 1 Diabetes Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Type 1 Diabetes Market
- 8.1. Asia-Pacific Type 1 Diabetes Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Type 1 Diabetes Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Type 1 Diabetes Market, Segmentation By Device, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Type 1 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Type 1 Diabetes Market
- 9.1. China Type 1 Diabetes Market Overview
- 9.2. China Type 1 Diabetes Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Type 1 Diabetes Market, Segmentation By Device, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Type 1 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Type 1 Diabetes Market
- 10.1. India Type 1 Diabetes Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Type 1 Diabetes Market, Segmentation By Device, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Type 1 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Type 1 Diabetes Market
- 11.1. Japan Type 1 Diabetes Market Overview
- 11.2. Japan Type 1 Diabetes Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Type 1 Diabetes Market, Segmentation By Device, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Type 1 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Type 1 Diabetes Market
- 12.1. Australia Type 1 Diabetes Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Type 1 Diabetes Market, Segmentation By Device, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Type 1 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Type 1 Diabetes Market
- 13.1. Indonesia Type 1 Diabetes Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Type 1 Diabetes Market, Segmentation By Device, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Type 1 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Type 1 Diabetes Market
- 14.1. South Korea Type 1 Diabetes Market Overview
- 14.2. South Korea Type 1 Diabetes Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Type 1 Diabetes Market, Segmentation By Device, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Type 1 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Type 1 Diabetes Market
- 15.1. Western Europe Type 1 Diabetes Market Overview
- 15.2. Western Europe Type 1 Diabetes Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Type 1 Diabetes Market, Segmentation By Device, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Type 1 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Type 1 Diabetes Market
- 16.1. UK Type 1 Diabetes Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Type 1 Diabetes Market, Segmentation By Device, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Type 1 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Type 1 Diabetes Market
- 17.1. Germany Type 1 Diabetes Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Type 1 Diabetes Market, Segmentation By Device, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Type 1 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Type 1 Diabetes Market
- 18.1. France Type 1 Diabetes Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Type 1 Diabetes Market, Segmentation By Device, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Type 1 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Type 1 Diabetes Market
- 19.1. Italy Type 1 Diabetes Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Type 1 Diabetes Market, Segmentation By Device, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Type 1 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Type 1 Diabetes Market
- 20.1. Spain Type 1 Diabetes Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Type 1 Diabetes Market, Segmentation By Device, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Type 1 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Type 1 Diabetes Market
- 21.1. Eastern Europe Type 1 Diabetes Market Overview
- 21.2. Eastern Europe Type 1 Diabetes Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Type 1 Diabetes Market, Segmentation By Device, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Type 1 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Type 1 Diabetes Market
- 22.1. Russia Type 1 Diabetes Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Type 1 Diabetes Market, Segmentation By Device, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Type 1 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Type 1 Diabetes Market
- 23.1. North America Type 1 Diabetes Market Overview
- 23.2. North America Type 1 Diabetes Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Type 1 Diabetes Market, Segmentation By Device, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Type 1 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Type 1 Diabetes Market
- 24.1. USA Type 1 Diabetes Market Overview
- 24.2. USA Type 1 Diabetes Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Type 1 Diabetes Market, Segmentation By Device, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Type 1 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Type 1 Diabetes Market
- 25.1. Canada Type 1 Diabetes Market Overview
- 25.2. Canada Type 1 Diabetes Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Type 1 Diabetes Market, Segmentation By Device, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Type 1 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Type 1 Diabetes Market
- 26.1. South America Type 1 Diabetes Market Overview
- 26.2. South America Type 1 Diabetes Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Type 1 Diabetes Market, Segmentation By Device, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Type 1 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Type 1 Diabetes Market
- 27.1. Brazil Type 1 Diabetes Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Type 1 Diabetes Market, Segmentation By Device, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Type 1 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Type 1 Diabetes Market
- 28.1. Middle East Type 1 Diabetes Market Overview
- 28.2. Middle East Type 1 Diabetes Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Type 1 Diabetes Market, Segmentation By Device, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Type 1 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Type 1 Diabetes Market
- 29.1. Africa Type 1 Diabetes Market Overview
- 29.2. Africa Type 1 Diabetes Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Type 1 Diabetes Market, Segmentation By Device, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Type 1 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Type 1 Diabetes Market Competitive Landscape And Company Profiles
- 30.1. Type 1 Diabetes Market Competitive Landscape
- 30.2. Type 1 Diabetes Market Company Profiles
- 30.2.1. Johnson and Johnson Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck and Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Sanofi-Aventis LLC. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
31. Type 1 Diabetes Market Other Major And Innovative Companies
- 31.1. Medtronic Plc
- 31.2. Eli Lilly and Co Ltd.
- 31.3. Novo Nordisk A/S
- 31.4. Vertex Pharmaceuticals Incorporated
- 31.5. Dexcom Inc.
- 31.6. Insulet Corporation
- 31.7. Tandem Diabetes Care Inc.
- 31.8. Adaptive Biotechnologies Corporation
- 31.9. Xeris Pharmaceuticals Inc.
- 31.10. MannKind Corporation
- 31.11. Biocon Ltd.
- 31.12. Virta Health Corp.
- 31.13. Bigfoot Biomedical Inc.
- 31.14. ViaCyte Inc.
- 31.15. Beta Bionics Inc.
32. Global Type 1 Diabetes Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Type 1 Diabetes Market
34. Recent Developments In The Type 1 Diabetes Market
35. Type 1 Diabetes Market High Potential Countries, Segments and Strategies
- 35.1 Type 1 Diabetes Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Type 1 Diabetes Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Type 1 Diabetes Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
